This proposal will combine the expertise of two groups of investigators -- an active program performing clinical intervention trials to treat rheumatoid arthritis and a group of immunopathologists with new developed techniques to analyze cytokine and other key molecules in inflammatory tissue. Synovial tissue will be obtained using needle arthroscopy with visually directed biopsies before and after therapy with several biologic agents and the tissue thoroughly evaluated using a combined analysis of immunohistochemistry, in situ hybridization, an quantitative competitive reverse transcript/PCR (QC-RT-PC). Cytokine expression will also be determined by ELISA technique in synovial fluid obtained at the same time as the synovial biopsy. The central focus of this application is to examine two hypotheses concerning the pathophysiology of inflammatory synovitis in rheumatoid arthritis -- that continual local activation of T cells to produce Th1-like cytokines is the key mechanism to maintain chronicity in synovitis and that TNFalpha is the primary effector of local inflammatory changes. Although some analysis of synovial fluid specimens will be performed, the emphasis will be on examining the effects of these biologics on synovial tissue, using the complementary techniques of in situ hybridization, monoclonal antibody based immunohistochemical analysis, and a novel approach to QC-RT- PCR. Since most clinical trials of biologics have shown heterogenous responses among individual patients, the immunophenotypic pattern of lesions prior to treatment associated with clinical treatment response and the specific molecular changes within inflammed synovium that accompany clinical improvement will be documented.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR044384-05
Application #
6171606
Study Section
Special Emphasis Panel (SRC (40))
Program Officer
Gretz, Elizabeth
Project Start
1996-05-05
Project End
2002-04-30
Budget Start
2000-05-01
Budget End
2002-04-30
Support Year
5
Fiscal Year
2000
Total Cost
$259,634
Indirect Cost
Name
University of Alabama Birmingham
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Hida, Daisuke; Danielson, Ben T; Knudson, Cheryl B et al. (2015) CD44 knock-down in bovine and human chondrocytes results in release of bound HYAL2. Matrix Biol 48:42-54
Moreland, Larry W; O'Dell, James R (2002) Glucocorticoids and rheumatoid arthritis: back to the future? Arthritis Rheum 46:2553-63
Bridges Jr, S Louis; Jenq, Grace; Moran, Molly et al. (2002) Single-nucleotide polymorphisms in tumor necrosis factor receptor genes: definition of novel haplotypes and racial/ethnic differences. Arthritis Rheum 46:2045-50
Moreland, L W; Bucy, R P; Weinblatt, M E et al. (2002) Immune function in patients with rheumatoid arthritis treated with etanercept. Clin Immunol 103:13-21
Moreland, L W (2001) Potential biologic agents for treating rheumatoid arthritis. Rheum Dis Clin North Am 27:445-91
Robinson, W H; Genovese, M C; Moreland, L W (2001) Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 44:1977-83
Koopman, W J; Moreland, L W (1998) Rheumatoid arthritis: anticytokine therapies on the horizon. Ann Intern Med 128:231-3